Development and validation of HPLC-MS/MS technique for the quantitative determination of a new derivative of sydnonymine and its metabolites in rabbit plasma

Introduction. BBP2023 is a new drug candidate of the sydnonymine group with cerebral vasodilating activity and procognitive properties. The pharmacological effects of BBP2023 are due to the presence of active metabolites. To conduct pharmacokinetic studies at the preclinical stage, it is necessary to develop a bioanalytical method for the determination of BBP2023 and its metabolites in rabbit blood plasma.

Aim. Development and validation of a chromatography-mass spectrometric method for the quantitative determination of a new derivative of sydnonymine and its metabolites in rabbit blood plasma.

Materials and methods. Quantitative determination of BBP2023 in rabbit blood plasma was performed by HPLC-MS/MS. The biomaterial sample preparation was based on the method of protein precipitation with methanol. Chromatographic separation was performed with a mixture of deionized water and acetonitrile in a gradient mode on a ZORBAX Eclipse XDB-C18 analytical column (4.6 × 50 mm, 5 μm) using an Agilent 1260 Infinity II chromatograph. Detection was performed in the MRM mode using an AB Sciex QTRAP 3200 MD mass spectrometer. N-(ethoxycarbonyl)-3-(4-methylpentan-2-yl)sydnonymine was used as the internal standard.

Results and discussion. The method for sample preparation of rabbit blood plasma has been developed, optimal conditions for chromatography and detection of the studied compound and its metabolites have been selected. The bioanalytical method has been validated according to the following parameters: selectivity, matrix effect, recovery rate, carry-over effect, linearity of the calibration range, lower limit of quantitative determination, intra- and inter-run accuracy and precision, as well as stability of analytes and the internal standard at the analysis stages.

Conclusion. A method for the quantitative determination of a new derivative of sydnonymine BBP2023 and its metabolites in rabbit blood plasma using HPLC-MS/MS has been developed and validated. The confirmed analytical ranges for BBP2023, BBP2023 A and BBP2023 C were 5.0–500.0 ng/ml (5.0–1000.0 ng/ml for geranamine). The method was used in the analytical part of the preclinical pharmacokinetic study of BBP2023 in rabbits.

1. Zivadinov R., Chung C.-P. Potential involvement of the extracranial venous system in central nervous system disorders and aging. BMC Medicine. 2013;11:260. DOI: 10.1186/1741-7015-11-260.

2. Kolmos M., Christoffersen L., Kruuse C. Recurrent ischemic stroke a systematic review and meta-analysis. Journal of Stroke and Cerebrovascular Diseases. 2021;30(8):105935. DOI: 10.1016/j.jstrokecerebrovasdis.2021.105935.

3. Ding R., Zhang H. Efficacy of very early mobilization in patients with acute stroke: a systematic review and meta-analysis. Annals of Palliative Medicine. 2021;10(11):1177611784. DOI: 10.21037/apm-21-2997.

4. Shahid J., Kashif A., Shahid M. K. A comprehensive review of physical therapy interventions for stroke rehabilitation: impairment-based approaches and functional goals. Brain Sciences. 2023;13(5):717. DOI: 10.3390/brainsci13050717.

5. Yuan M., Xiao Z.-L., Zhou H.-Y., Rao W., Huang G., Nie H.-B., Cao W.-F., Xu R.-S. Bipolar disorder and the risk for stroke incidence and mortality: a meta-analysis. Neurological Sciences. 2022;43(1):467–476. DOI: 10.1007/s10072-021-05348-2.

6. Rajeev V., Chai Y. L., Poh L., Selvaraji S., Fann D. Y., Jo D.-G., De Silva T. M., Drummond G. R., Sobey C. G., Arumugam T. V., Chen C. P., Lai M. K. P. Chronic cerebral hypoperfusion: a critical feature in unravelling the etiology of vascular cognitive impairment. Acta Neuropathologica Communications. 2023;11(1):93. DOI: 10.1186/s40478-023-01590-1.

7. Kulesh A. A., Emelin A. Yu., Bogolepova A. N., Doronina O. B., Zakharov V. V., Kolokolov O. V., Kotov S. V., Korsunskaya L. L., Kutlubaev M. A., Laskov V. B., Levin O. S., Parfenov V. A. Clinical manifestations and issues of diagnosis of chronic cerebrovascular disease (chronic cerebral ischemia) at an early (pre-dementia) stage. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(1):4–12. DOI: 10.14412/2074-2711-2021-1-4-12.

8. Rajeev V., Fann D. Y., Dinh Q. N., Kim H. A., De Silva T. M., Lai M. K. P., Chen C. L.-H., Drummond G. R., Sobey C. G., Arumugam T. V. Pathophysiology of blood brain barrier dysfunction during chronic cerebral hypoperfusion in vascular cognitive impairment. Theranostics. 2022;12(4):1639–1658. DOI: 10.7150/thno.68304.

9. Cross J. G., May B. R., Mai P. Q. M., Anderson E., Welsh C., Chandran S., Chorath K. T., Herr S., Gonzalez D. A systematic review and evaluation of post-stroke depression clinical practice guidelines. Journal of Stroke and Cerebrovascular Diseases. 2023;32(9):107292. DOI: 10.1016/j.jstrokecerebrovasdis.2023.107292.

10. Castello J. P., Pasi M., Kubiszewski P., Abramson J. R., Charidimou A., Kourkoulis C., DiPucchio Z., Schwab K., Anderson C. D., Gurol M. E., Greenberg S. M., Rosand J., Viswanathan A., Biffi A. Cerebral small vessel disease and depression among intracerebral hemorrhage survivors. Stroke. 2022;53(2):523–531. DOI: 10.1161/STROKEAHA.121.035488.

11. Ištoňová M., Dorko E., Knap V., Stehlíková B., Murgová A., Ondová P., Rimárová K. Assessment of depressive disorders and states of anxiety in patients following cerebrovascular accidents in connection with health care provision. Central European Journal of Public Health. 2024;32(Suppl):S18–S24. DOI: 10.21101/cejph.a7888.

12. Ghosh P. A., Chaudhury S., Rohatgi S. Assessment of Depression, Anxiety, Stress, Quality of Life, and Fatigue in Patients After a Cerebrovascular Accident. Cureus. 2024;16(10):e72051. DOI: 10.7759/cureus.72051.

13. McAleese N., Guzman A., O’Rourke S. J., Gillespie D. C. Post-stroke emotionalism: a qualitative investigation. Disability and Rehabilitation. 2021;43(2):192–200. DOI: 10.1080/09638288.2019.1620876.

14. Wu J., Yin W., Huang Z., Zhang Y., Jia J., Cheng H., Kang F., Huang K., Sun T., Tian J., Xu X., Zhang Y. Design, synthesis, and biological evaluation of organic nitrite (NO2–) donors as potential anticerebral ischemia agents. Journal of Medicinal Chemistry. 2021;64(15):10919–10933. DOI: 10.1021/acs.jmedchem.1c00282.

15. Archavlis E., Nievas M. C. Y. Cerebral vasospasm: a review of current developments in drug therapy and research. Journal of Pharmaceutical Technology and Drug Research. 2013;2(1):18. DOI: 10.7243/2050-120X-2-18.

16. Idocin A. F., Specklin S., Taran F. Sydnonimines: synthesis, properties and applications in chemical biology. Chemical Communications. 2025;61(31):5704–5718. DOI: 10.1039/d5cc00535c.

17. Popov N. S., Baranov M. S., Balabanyan V. Yu. Targeted study of the pharmacokinetics of the leading compounds from the group of sydnonymines as a basis for the creation of vasodilators with predominantly central action. Translational medicine. 2024;11(S2):112. (In Russ.)

18. Docherty J. R., Alsufyani H. A. Pharmacology of drugs used as stimulants. The Journal of Clinical Pharmacology. 2021;61:S53–S69. DOI: 10.1002/jcph.1918.

19. Popov N. S., Gavrilenko D. A., Pavlov R. D., Baranov M. S., Kaurova D. E., Myasnyanko I. N., Ivanov D. S., Balabanyan V. Yu. Study of the biotransformation of a new sydnonimine derivative with predominant cerebral vasodilatory activity. Research Results in Pharmacology. 2025;11(4):258–271. DOI: 10.18413/rrpharmacology.11.1042.

20. Popov N. S., Terekhov V. M., Baranov M. S., Balabanyan V. Yu., Kaurova D. E., Myasnyanko I. N., et al. In vivo assessment of the role of liver metabolism in sydnone imine biotransformation. Bulletin of Russian State Medical University. 2025;(3):50–57. (In Russ.) DOI: 10.24075/vrgmu.2025.026.

21. Popov N. S., Gavrilenko D. A., Baranov M. S., Kaurova D. E., Myasnyanko I. N., Balabanyan V. Yu. Study of the pharmacokinetics of a new sidnonymine derivative in rabbits with various routes of administration. Pharmacokinetics and Pharmacodynamics. 2025;(4):69–76. (In Russ.) DOI: 10.37489/2587-7836-2025-4-69-76.